Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
23814 | 334 | 38.6 | 83% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
630 | 3 | HEPATIC ENCEPHALOPATHY//ASYMMETRIC DIMETHYLARGININE//HYPERAMMONEMIA | 13067 |
2078 | 2 | ASYMMETRIC DIMETHYLARGININE//ARGINASE//ADMA | 5239 |
23814 | 1 | ARGININE DEIMINASE//ARGININE DEPRIVATION//ARGININOSUCCINATE SYNTHETASE | 334 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | ARGININE DEIMINASE | authKW | 3433020 | 20% | 57% | 66 |
2 | ARGININE DEPRIVATION | authKW | 1210002 | 4% | 88% | 15 |
3 | ARGININOSUCCINATE SYNTHETASE | authKW | 686443 | 9% | 26% | 29 |
4 | ADI PEG20 | authKW | 548536 | 2% | 100% | 6 |
5 | RECOMBINANT HUMAN ARGINASE | authKW | 457113 | 1% | 100% | 5 |
6 | AZURIN | authKW | 307082 | 8% | 12% | 27 |
7 | ARGININE DEIMINASE ADI | authKW | 274268 | 1% | 100% | 3 |
8 | H8 EPITOPE | authKW | 274268 | 1% | 100% | 3 |
9 | PHOENIX PHARMACOL INC | address | 274268 | 1% | 100% | 3 |
10 | RECOMBINANT ARGININE DEIMINASE | authKW | 274268 | 1% | 100% | 3 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 1842 | 39% | 0% | 130 |
2 | Cell Biology | 249 | 16% | 0% | 52 |
3 | Biochemistry & Molecular Biology | 193 | 23% | 0% | 78 |
4 | Biotechnology & Applied Microbiology | 146 | 10% | 0% | 34 |
5 | Biophysics | 139 | 8% | 0% | 28 |
6 | Medicine, Research & Experimental | 31 | 5% | 0% | 16 |
7 | Pharmacology & Pharmacy | 29 | 8% | 0% | 27 |
8 | Hematology | 27 | 4% | 0% | 12 |
9 | Biochemical Research Methods | 16 | 3% | 0% | 11 |
10 | Microbiology | 14 | 4% | 0% | 14 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PHOENIX PHARMACOL INC | 274268 | 1% | 100% | 3 |
2 | SYLVERSTER COMPREHENS CANC | 182845 | 1% | 100% | 2 |
3 | ADV SCI TECHNOL COMMERICALIZAT | 91423 | 0% | 100% | 1 |
4 | AMBULATORY SERV ADM | 91423 | 0% | 100% | 1 |
5 | BIOMEDES | 91423 | 0% | 100% | 1 |
6 | BIOTECHNOL BIO ENGN | 91423 | 0% | 100% | 1 |
7 | CANC DRUG RD | 91423 | 0% | 100% | 1 |
8 | GENET ONCOL ONCOL TRANSLAZ | 91423 | 0% | 100% | 1 |
9 | GUT MICROBIOL IMMUNOL GRP CENT EXCELLENCE ADV S | 91423 | 0% | 100% | 1 |
10 | HISTOPATHOL ISH | 91423 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF MOLECULAR RECOGNITION | 3664 | 2% | 1% | 7 |
2 | BIOENGINEERED | 3019 | 1% | 1% | 3 |
3 | RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY | 1403 | 1% | 1% | 2 |
4 | CANCER BIOCHEMISTRY BIOPHYSICS | 992 | 1% | 1% | 2 |
5 | CELL DEATH & DISEASE | 961 | 1% | 0% | 5 |
6 | TRANSLATIONAL ONCOLOGY | 663 | 1% | 0% | 2 |
7 | BRITISH JOURNAL OF CANCER | 602 | 3% | 0% | 11 |
8 | CANCER LETTERS | 599 | 3% | 0% | 9 |
9 | INVESTIGATIONAL NEW DRUGS | 566 | 1% | 0% | 4 |
10 | MOLECULAR CANCER THERAPEUTICS | 554 | 1% | 0% | 5 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ARGININE DEIMINASE | 3433020 | 20% | 57% | 66 | Search ARGININE+DEIMINASE | Search ARGININE+DEIMINASE |
2 | ARGININE DEPRIVATION | 1210002 | 4% | 88% | 15 | Search ARGININE+DEPRIVATION | Search ARGININE+DEPRIVATION |
3 | ARGININOSUCCINATE SYNTHETASE | 686443 | 9% | 26% | 29 | Search ARGININOSUCCINATE+SYNTHETASE | Search ARGININOSUCCINATE+SYNTHETASE |
4 | ADI PEG20 | 548536 | 2% | 100% | 6 | Search ADI+PEG20 | Search ADI+PEG20 |
5 | RECOMBINANT HUMAN ARGINASE | 457113 | 1% | 100% | 5 | Search RECOMBINANT+HUMAN+ARGINASE | Search RECOMBINANT+HUMAN+ARGINASE |
6 | AZURIN | 307082 | 8% | 12% | 27 | Search AZURIN | Search AZURIN |
7 | ARGININE DEIMINASE ADI | 274268 | 1% | 100% | 3 | Search ARGININE+DEIMINASE+ADI | Search ARGININE+DEIMINASE+ADI |
8 | H8 EPITOPE | 274268 | 1% | 100% | 3 | Search H8+EPITOPE | Search H8+EPITOPE |
9 | RECOMBINANT ARGININE DEIMINASE | 274268 | 1% | 100% | 3 | Search RECOMBINANT+ARGININE+DEIMINASE | Search RECOMBINANT+ARGININE+DEIMINASE |
10 | ARGININE STARVATION | 243791 | 1% | 67% | 4 | Search ARGININE+STARVATION | Search ARGININE+STARVATION |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | QIU, FM , HUANG, J , SUI, MH , (2015) TARGETING ARGININE METABOLISM PATHWAY TO TREAT ARGININE-DEPENDENT CANCERS.CANCER LETTERS. VOL. 364. ISSUE 1. P. 1 -7 | 57 | 81% | 13 |
2 | PATIL, MD , BHAUMIK, J , BABYKUTTY, S , BANERJEE, UC , FUKUMURA, D , (2016) ARGININE DEPENDENCE OF TUMOR CELLS: TARGETING A CHINK IN CANCER'S ARMOR.ONCOGENE. VOL. 35. ISSUE 38. P. 4957 -4972 | 81 | 43% | 2 |
3 | PHILLIPS, MM , SHEAFF, MT , SZLOSAREK, PW , (2013) TARGETING ARGININE-DEPENDENT CANCERS WITH ARGININE-DEGRADING ENZYMES: OPPORTUNITIES AND CHALLENGES.CANCER RESEARCH AND TREATMENT. VOL. 45. ISSUE 4. P. 251 -262 | 53 | 58% | 40 |
4 | HAN, RZ , XU, GC , DONG, JJ , NI, Y , (2016) ARGININE DEIMINASE: RECENT ADVANCES IN DISCOVERY, CRYSTAL STRUCTURE, AND PROTEIN ENGINEERING FOR IMPROVED PROPERTIES AS AN ANTI-TUMOR DRUG.APPLIED MICROBIOLOGY AND BIOTECHNOLOGY. VOL. 100. ISSUE 11. P. 4747 -4760 | 41 | 72% | 1 |
5 | KELLY, MP , JUNGBLUTH, AA , WU, BW , BOMALASKI, J , OLD, LJ , RITTER, G , (2012) ARGININE DEIMINASE PEG20 INHIBITS GROWTH OF SMALL CELL LUNG CANCERS LACKING EXPRESSION OF ARGININOSUCCINATE SYNTHETASE.BRITISH JOURNAL OF CANCER. VOL. 106. ISSUE 2. P. 324 -332 | 28 | 74% | 28 |
6 | FEUN, LG , KUO, MT , SAVARAJ, N , (2015) ARGININE DEPRIVATION IN CANCER THERAPY.CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE. VOL. 18. ISSUE 1. P. 78 -82 | 18 | 90% | 14 |
7 | FEUN, L , YOU, M , WU, CJ , KUO, MT , WANGPAICHITR, M , SPECTOR, S , SAVARAJ, N , (2008) ARGININE DEPRIVATION AS A TARGETED THERAPY FOR CANCER.CURRENT PHARMACEUTICAL DESIGN. VOL. 14. ISSUE 11. P. 1049-1057 | 34 | 54% | 79 |
8 | MCALPINE, JA , LU, HT , WU, KC , KNOWLES, SK , THOMSON, JA , (2014) DOWN-REGULATION OF ARGININOSUCCINATE SYNTHETASE IS ASSOCIATED WITH CISPLATIN RESISTANCE IN HEPATOCELLULAR CARCINOMA CELL LINES: IMPLICATIONS FOR PEGYLATED ARGININE DEIMINASE COMBINATION THERAPY.BMC CANCER. VOL. 14. ISSUE . P. - | 27 | 63% | 8 |
9 | FEUN, LG , MARINI, A , WALKER, G , ELGART, G , MOFFAT, F , RODGERS, SE , WU, CJ , YOU, M , WANGPAICHITR, M , KUO, MT , ET AL (2012) NEGATIVE ARGININOSUCCINATE SYNTHETASE EXPRESSION IN MELANOMA TUMOURS MAY PREDICT CLINICAL BENEFIT FROM ARGININE-DEPLETING THERAPY WITH PEGYLATED ARGININE DEIMINASE.BRITISH JOURNAL OF CANCER. VOL. 106. ISSUE 9. P. 1481-1485 | 19 | 86% | 31 |
10 | STASYK, OV , BORETSKY, YR , GONCHAR, MV , SIBIRNY, AA , (2015) RECOMBINANT ARGININE-DEGRADING ENZYMES IN METABOLIC ANTICANCER THERAPY AND BIOANALYTICS.CELL BIOLOGY INTERNATIONAL. VOL. 39. ISSUE 3. P. 246 -252 | 21 | 78% | 3 |
Classes with closest relation at Level 1 |